Skip to main content
. 2018 Nov 15;7(11):212. doi: 10.3390/cells7110212

Figure 2.

Figure 2

Mechanisms of acquired resistance to osimertinib [32,33,34,35,36]. EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition factor; HER2, human epidermal growth factor receptor 2; FGFR1, fibroblast growth factor receptor 1; KRAS, Kirsten rat sarcoma viral oncogene homolog; PIK3CA, phosphoinositide-3-kinase P110α catalytic subunit; SCLC, small-cell lung cancer.